Home / Markets / Capital Market News / Lupin launches Mirabegron Extended-Release Tablets in US

Lupin launches Mirabegron Extended-Release Tablets in US

Last Updated : Sep 04 2024 | 3:31 PM IST

Lupin announced the launch of Mirabegron Extended-Release Tablets, 50 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 50 mg of Astellas Pharma Global Development, Inc.

Mirabegron Extended-Release Tablets, 50 mg had estimated annual sales of USD 1,600 million in the U.S. (IQVIA MAT July 2024).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content